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Background: [18F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A,
the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation
dosimetry of [18F]UCB-H in a preclinical trial and to determine the maximum injectable dose according to
guidelines for human biomedical research. The radiation dosimetry was derived by organ harvesting and dynamic
micro positron emission tomography (PET) imaging in mice, and the results of both methods were compared.
Methods: Twenty-four male C57BL-6 mice were injected with 6.96 ± 0.81 MBq of [18F]UCB-H, and the
biodistribution was determined by organ harvesting at 2, 5, 10, 30, 60, and 120 min (n = 4 for each time point).
Dynamic microPET imaging was performed on five male C57BL-6 mice after the injection of 9.19 ± 3.40 MBq of
[18F]UCB-H. A theoretical dynamic bladder model was applied to simulate urinary excretion. Human radiation dose
estimates were derived from animal data using the International Commission on Radiological Protection 103 tissue
weighting factors.
Results: Based on organ harvesting, the urinary bladder wall, liver and brain received the highest radiation dose
with a resulting effective dose of 1.88E-02 mSv/MBq. Based on dynamic imaging an effective dose of 1.86E-02 mSv/
MBq was calculated, with the urinary bladder wall and liver (brain was not in the imaging field of view) receiving
the highest radiation.
Conclusions: This first preclinical dosimetry study of [18F]UCB-H showed that the tracer meets the standard criteria
for radiation exposure in clinical studies. The dose-limiting organ based on US Food and Drug Administration (FDA)
and European guidelines was the urinary bladder wall for FDA and the effective dose for Europe with a maximum
injectable single dose of approximately 325 MBq was calculated. Although microPET imaging showed significant
deviations from organ harvesting, the Pearson’s correlation coefficient between radiation dosimetry derived by
either method was 0.9666.
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Epilepsy is a chronic neurological disorder characterized
by seizures and abnormal electroencephalographic activ-
ity. It affects people of all ages with more than 50 mil-
lion cases worldwide. In contrast to other antiepileptic
drugs, levetiracetam (Keppra®, UCB Pharma Ltd., Slough,
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in any medium, provided the original work is pbinding to the neuronal synaptic vesicle protein 2A
(SV2A) in the brain [1]. SV2 proteins are critical to
proper nervous system function, and they have been
demonstrated to be involved in vesicle trafficking. How-
ever, the specific role of SV2A in epilepsy remains
unclear. The newly developed fluorine-18 radiolabelled
positron emission tomography (PET) imaging agent
[18F]UCB-H shows a nanomolar affinity for the human
SV2A protein and will be of great value in studying the
function of SV2A in diseases of the central nervous sys-
tem [2].n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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human clinical trials and good clinical practice is a pre-
clinical dosimetry study in animals. This enables the pre-
diction of dose limits in humans that will keep radiation
doses below harmful limits while still producing diag-
nostically beneficial images. Radiation estimates for
humans derived from small animals are traditionally
obtained by ex vivo tissue distribution (TD) studies,
where organs are harvested post-injection at several time
points to establish the biodistribution. However, dynamic
imaging approaches in small animals using microPET
are a promising alternative, because the complete bio-
distribution of the radiopharmaceutical can be obtained
within a single in vivo scan with a much higher time
resolution. The aims of this study were to predict the ra-
diation dose given to humans based on the distribution
of [18F]UCB-H in mice and to determine the maximum
injectable dose according to radiation guidelines in bio-
medical research. Additionally, the TD and microPET




[18F]UCB-H was obtained in a four-step radiosynthesis.
Briefly, this consisted of nucleophilic labeling of a pyri-
dine precursor, reductive amination of the labeled prod-
uct, and internal cyclisation. Specific activity was higher
than 500 MBq/μg at the end of synthesis.
Animals
Male C57BL-6 mice were initially obtained at 5 weeks of
age from Charles River Laboratories (Brussels, Belgium)
and subsequently bred at the Animal Facility of the
GIGA-University of Liège (BE-LA 2610359). The ani-
mals were housed under standard 12h:12h light/dark
conditions with food and water available ad libitum. All
experimental procedures and protocols used in this inves-
tigation were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of
Liège.
Tissue distribution
The data acquisition and analysis were conducted in ac-
cordance with MIRD pamphlet no. 16 [3]. For the TD of
[18F]UCB-H, 24 male C57BL-6 mice (23.96 ± 1.31 g
[20.6 to 26.1 g]) were injected with an iv bolus of 6.96 ±
0.81 MBq [5.18 to 8.06 MBq] [18F]UCB-H via the tail vein
under isoflurane anesthesia. Anesthesia was maintained
until sacrificed by decapitation after 2, 5, 10, 30, 60, and
120 min (n = 4 for each time point). Blood samples were
obtained (0.5 to 1 ml), and the following organs were
harvested by dissection: the brain, bone (femur), liver (par-
tial), kidney, heart, spleen, intestine (partial), pancreas,adrenals, testes, skin (partial), muscle (partial/thigh),
stomach, lung, and bladder. All organs were weighed
(NewClassic ML, Mettler Toledo, Switzerland), and the
activity was quantified using a gamma well counter (Cobra
II Auto-Gamma, Perkin-Elmer, Waltham, MA, USA),
resulting in the average activity per gram of tissue in mice.
The gamma well counter was calibrated measuring a
known quantity of 18F activity (quantified using a cali-
brated gamma spectrometer: high purity 30% germanium
GR3020 from Canberra Industries, Meriden, CT, USA),
thereby obtaining a calibration factor between real and
measured activity. The measurement uncertainty was
evaluated to be ±5%.
Dynamic microPET imaging
Dynamic microPET imaging was performed on five male
C57BL-6 mice with an average weight of 29.72 ± 6.70 g
[24.2 to 40.8 g]. 9.19 ± 3.40 MBq [3.84 to 14.20 MBq]
[18F]UCB-H was administered via the tail vein as bolus.
All procedures were performed under isoflurane
anesthesia. Co-registered micro-computed tomography
(CT) images were acquired with an eXplore 120 microCT
(Gamma Medica, USA/GE Healthcare, Sevenoaks, Kent,
UK) [4] to obtain anatomical information for segmenta-
tion. An iodine-based contrast agent (1:10 dilution of
iobitridol-XENETIX300, Guerbet, Roissy, France) was ad-
ministered in the peritoneal cavity prior to microCT to
aid full organ segmentation. All microCT images were
reconstructed using Feldkamp’s filtered backprojection
algorithm [5] with a cutoff at the Nyquist frequency and
an isotropic voxel size of 100 μm. The same MINERVE
animal cell bed (Equipement Veterinaire Minerve,
Esternay, France) was used in both imaging modalities
to provide anesthesia, physiological control, monitoring
of respiration, and simplified co-registration of the im-
ages. Dynamic microPET scans over 120 min were ac-
quired using a Siemens Concorde Focus 120 microPET
(Siemens, Munich, Germany) [6] and followed by trans-
mission measurement with 57Co point source. In order
to obtain dynamic imaging data for as many organs as
possible, the field of view of the scanner was positioned
on the chest and lower body disregarding the brain.
The list-mode data were histogrammed into three-
dimensional (3D) sinograms by Fourier rebinning [7]
and reconstructed by filtered backprojection with a
ramp filter cutoff at the Nyquist frequency. Corrections
for randoms, dead time, and attenuation were applied
but not scatter correction, since it was shown by Bahri
et al. [8] that no benefit for quantification is gained by
applying scatter correction for the Focus-F120. No
partial volume correction was performed on the acquired
data. A set of 3D images was reconstructed in a 256 ×
256 × 95 matrix with a pixel size of 0.4 × 0.4 × 0.8 mm.
The dynamic time framing was as follows: 6 × 5 s, 6 ×
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6 × 600 s, and all data were decay corrected to the begin-
ning of each individual frame.
MicroCT and microPET images were co-registered
using a landmark-based approach. Volumes of interest
(VOIs) were drawn manually by a single observer on the
microCT images using PMOD (Version 3.306, PMOD
Technologies, Zurich, Switzerland). This allowed the de-
lineation of the following organs: the heart, lung, liver,
kidneys, and testes (referred to as ‘dynamic whole’). The
average organ activity per volume was obtained from the
co-registered microPET images. Additionally, VOIs in
the shape of spheres with a radius of 2 mm were placed
in the center of the same organs to limit the impact of
partial volume effects on the quantification and used for
dosimetry (referred to as ‘dynamic single’). For the heart,
one VOI was positioned over the myocardium and parts
of the chambers; for the liver, two VOIs were placed in
the center of the organ; for lungs, kidneys, and testes,
one VOI was placed in the center of each organ (i.e., left
and right wing for lungs, left and right organ for kidneys
and testes). MicroPET calibration for conversion of
counts/pixel in Bq/ml was performed as recommended
by the manufacturer. Accuracy of the technique has
been reported to be better than 2% [8].
Dosimetry analysis
When using animal data to predict human dosimetry, an
interspecies extrapolation is necessary to account for dif-
ferences between animal and human. A commonly used
method in preclinical imaging is that of Kirshner et al.
[9], which is based on a linear scaling of the percent up-
take in the animal by the ratio of the organ weights and


















The organ uptake in percentage of injected dose multi-
plied by the body weight in kilograms is assumed to be
constant across species, allowing for the calculation of
equivalent organ activities in humans from animal data.
Since the organ-to-body weight ratio is necessary to ex-
trapolate to humans and to create consistent time-
activity curves from the obtained average organ activity
per volume or gram of tissue, a ‘standard mouse’ was
created using six C57BL-6 mice. This ‘standard mouse’
allowed both organ density and the ratio of organ weight
to body weight to be calculated and a species average as-
sumed. The mice were weighed and then dissected to
determine the organ weight and density by microCT for
volume quantification. The mean total body weight was32.28 ± 3.98 g [28.6 to 39.8 g]. The following organs
were harvested: the brain, liver, kidney, heart, spleen,
testes, and lung. The organ volume was obtained from
the microCT images by a threshold-based segmentation
approach. All weights were finally scaled to a bodyweight
of 35 g. Only data from organs where the ratio of organ
weight to bodyweight was known were used for dosimetry.
Average organ activity per mass or volume was normal-
ized for injected dose and multiplied by organ weights or
organ volumes, respectively. Activity levels were linearly
interpolated, and only physical decay was assumed after the
last time point up to 10 h post-injection. Thus, a
homogenous activity distribution within each organ was
assumed, and biological clearance after 2 h post-injection
was neglected, assuming the activity was ‘trapped’ within
the source organ. The time-activity curves (TACs) were
then extrapolated from animal values to human values
using Equation 1. Human organ weights and body weight
were taken from the standard 70-kg adult male hermaphro-
ditic phantom implemented in the human dosimetry
software OLINDA/EXM (version 1.1) [10] and animal
organ weights from the standard mouse as described above.
In addition, TACs that were calculated based only on
animal organs (i.e., no extrapolation to human values) were
used to calculate additional dose estimates to provide an
estimation window for the human dosimetry (referred to as
‘NE’ for no extrapolation). Urine excretion data were
modeled using the implemented dynamic voiding bladder
module [11] in OLINDA/EXM. A voiding interval of 4 h
was assumed, and fractions of 0.5 to 0.3 of total injected
activity leaving the body via the urinary excretion system
with a biological half-life of 3 h were defined and separately
implemented. The same scenarios were implemented using
a voiding interval of 2 h to provide data for the impact of a
possible pre-scan hydration of the subject to decrease the
bladder dose. The residence time for each organ, which is
equal to the number of disintegrations within the source
organ, was calculated by trapezoidal numerical integration
of the TACs in MATLAB (version 7.12.0) as proposed in
literature [3,12]. Activity from other organs that could not
be extrapolated due to the unknown weight-to-body weight
ratio was assigned together with all unaccounted for activity
to the remainder, which is assumed to be homogenously
distributed throughout the remaining body. OLINDA/
EXM was used to calculate absorbed doses. The effective
doses in the standard 70-kg male human based on the
recent tissue weighting factors published in International
Commission on Radiological Protection (ICRP) 103 [13]
were calculated using Excel (version 2010, Microsoft,
Albuquerque, NM, USA) and are presented in the ‘Results’
section. For comparison purposes with other tracers and
previous works, the effective doses using old tissue
weighting factors from ICRP 60 [14] were also calculated
using OLINDA/EXM and were provided as additional files.
Figure 1 Mean human TACs derived by TD in mice (A: total, B: zoom in).
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points in different animals, each individual time point has
its own standard deviation (SD). Therefore, the SD of
residence times derived from the TD was calculated as
follows. Two additional animal TACs were constructed
using mean ± 1 SD of each individual time point of the
activity measurement. These two TACs were then extrapo-
lated to human values as previously described, and the
mean residence time corresponding to each TAC was
computed [15-17]. This provided a residence time window
which is expressed as a coefficient of variation in percent
(%CV) from the mean value. The residence time window
was used to calculate a minimum and maximum dose for
the TD, resulting more in a best and worst case scenario as
opposed to a real SD. The mean of best and worst case
scenario was used as the error for the measured absorbed
dose and reported as %CV of the mean value. For the
statistics of the microPET imaging, every scan was treated
separately, and mean and standard deviation expressed as
%CV were regularly calculated across scans. Correlations
between datasets were calculated by the Pearson product–
moment correlation coefficient in MATLAB.
Results
Figures 1 and 2 illustrate the human biodistribution of [18F]
UCB-H derived from animal TD and from microPETFigure 2 Mean human TACs derived by microPET imaging in mice (dyimaging based on sphere segmentation (dynamic single),
respectively. In both datasets, the highest initial activity
uptake was obtained within the liver with 29% and 18%,
respectively. However, brain data could not be derived from
PET data, as the brain was outside the scanner’s field of
view. Furthermore, the spleen could not be accurately
delineated in CT images in the absence of additional
contrast agents. TACs from whole organ segmentation
(dynamic whole) were provided as Additional file 1 (whole
TACs) and Additional file 2 (zoom in).
The mean residence times obtained by the TD and
dynamic microPET imaging with both segmentation
methods are presented in Table 1. The highest level of
disintegrations per organ occurred within the liver with
4.45E-01 h (TD), 1.93E-01 (dynamic whole), and 2.18E-01 h
(dynamic single). Bladder values are theoretical values
derived using the dynamic bladder module described above.
A cross section of all anatomical planes of the merged
PET/CT image is illustrated in Figure 3. High uptake in
liver, kidneys, bladder, and spinal cord can be observed.
The animal-derived dose estimations from the TD
method (Table 2) predicted that the highest absorbed dose
is received by the urinary bladder wall (modeled theoretical
value) with 1.54E-01 ± 5.00E-04 mGy/MBq, followed by
the liver with 5.84E-02 ± 7.35E-03 mGy/MBq and the brain
with 3.08E-02 ± 5.15E-03 mGy/MBq. The effective dosenamic single) (A: total, B: zoom in).
Table 1 Human residence times (h) (bladder fraction 0.5) derived by TD and dynamic imaging based on whole organ
segmentation and single spheres
Organ TD %CV Dynamic whole %CV Dynamic single %CV
Bladder (theoretical) 3.08E-01 - 3.08E-01 0.0 3.08E-01 0.0
Brain 1.74E-01 18.1 - - - -
Heart wall 1.79E-02 10.1 2.45E-02 11.6 2.39E-02 12.3
Kidneys 3.57E-02 10.5 1.67E-02 9.1 1.90E-02 13.2
Liver 4.45E-01 13.8 1.93E-01 6.7 2.18E-01 6.6
Lung 5.96E-02 9.8 1.13E-01 11.8 9.30E-02 14.8
Spleen 9.04E-03 13.6 - - - -
Testes 2.11E-03 12.7 1.04E-03 12.1 1.12E-03 12.8
Remaining body 1.58E + 00 6.7 1.98E + 00 1.4 1.97E + 00 1.2
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estimate, based on microPET imaging (dynamic single),
was received by the urinary bladder wall with 1.56E-01 ±
0.00E-00 mGy/MBq, followed by the liver with 3.14E-02 ±
1.97E-03 mGy/MBq (brain was not imaged). The effective
dose was 1.84E-02 ± 3.51E-04 mSv/MBq. Mean dose
estimates based on whole organ segmentation are provided
as Additional file 3 and effective doses for all three methods
obtained using old weighting factors form ICRP 60 as
Additional file 4.
In Table 3, the variation of the urinary bladder wall
absorbed dose when using fractions of 0.3 to 0.5 as
previously described is shown as well as its impact on the
effective dose for both methods. When reducing the
voiding interval to 2 h, the absorbed dose decreases to
9.21E-02 mGy/MBq (TD) for a bladder fraction of 0.5 and
to 5.94E-02 mGy/MBq (TD) for a bladder fraction of 0.3.
Discussion
The tissue distribution of [18F]UCB-H was obtained by
traditional organ harvesting at several time points in mice
as well as by dynamic microPET imaging to compare the
results of both methods. Dynamic microPET imaging is
an interesting alternative to organ harvesting. OrganFigure 3 Transverse (A), sagittal (B), and coronal (C) planes of merged
was averaged across all frames and smoothed using a Gaussian kernel of 1
kBq/cc in all planes (Brain outside FOV).harvesting requires many animals and can be labor
intensive. In dynamic microPET imaging, the complete
biodistribution can be obtained within a single scan.
Furthermore, it allows sampling of the activity distribution
with a much higher time resolution, thus catching early
blood uptake peaks in organs that are well perfused. Such
peaks could substantially contribute to organ radiation.
However, when comparing the residence times obtained
with all three techniques (Table 1), dynamic imaging (dy-
namic whole) alone significantly over- or underestimated
the activity within organs. This effect could be explained by
known imaging limitations in very small volumes such as
partial volume effect or spill over from nearby organs. Low
activity organs (i.e., the heart and lung) were overestimated
by 36 to 89% in the microPET images presumably due to
spill over from neighboring high activity organs (i.e., the
liver). All other organs were underestimated in microPET
images by 43 to 50%, which could be related to partial
volume effect. Deriving TACs from small sphere VOIs in
the center of organs (dynamic single) should have reduced
the impact of partial volume effect and slightly improved
quantification. However, underestimations of 49 to 53 %
and overestimations of 33 to 55% remained. A further
improvement in quantification might have been achievedaverage PET/CT image of a representative subject. PET image
× 1 × 2 mm in PMOD. The color scale was set to the range 80 to 800
Table 3 Influence of bladder fraction on urinary bladder
wall dose (UBW) and effective dose (ED)
Dose TD Dynamic single
Bladder fraction 0.3 UBW 9.67E-02 9.85E-02
ED 1.66E-02 1.63E-02
Bladder fraction 0.4 UBW 1.26E-01 1.28E-01
ED 1.77E-02 1.74E-02
Bladder fraction 0.5 UBW 1.54E-01 1.56E-01
ED 1.88E-02 1.84E-02
Variation of UBW absorbed dose in mGy/MBq and ED for ICRP 103 weighting
factors (mSv/MBq) for different bladder fractions and a voiding interval of 4 h.
Table 2 Human absorbed dose (mGy/MBq) and effective dose (mSv/MBq)
Target Organ TD %CV TD NE Dynamic single %CV Dynamic single NE
Adrenals 1.43E-02 1.7 1.65E-02 1.36E-02 1.0 1.44E-02
Brain 3.08E-02 16.7 2.05E-02 8.61E-03 1.1 8.27E-03
Breasts 7.71E-03 2.9 7.18E-03 8.88E-03 0.7 8.36E-03
Gallbladder wall 1.86E-02 4.3 2.26E-02 1.56E-02 1.7 1.75E-02
LLI wall 1.36E-02 4.0 1.28E-02 1.55E-02 0.8 1.52E-02
Small intestine 1.24E-02 3.2 1.22E-02 1.37E-02 0.5 1.37E-02
Stomach wall 1.11E-02 2.3 1.11E-02 1.20E-02 0.4 1.20E-02
ULI wall 1.25E-02 2.4 1.27E-02 1.34E-02 0.6 1.36E-02
Heart wall 1.76E-02 6.5 1.77E-02 2.09E-02 9.2 1.26E-02
Kidneys 2.96E-02 8.4 7.07E-02 1.87E-02 9.1 4.06E-02
Liver 5.84E-02 12.6 8.40E-02 3.14E-02 6.3 4.32E-02
Lungs 1.64E-02 6.7 1.11E-02 2.17E-02 12.0 1.23E-02
Muscle 9.82E-03 3.1 9.42E-03 1.10E-02 0.4 1.08E-02
Ovaries 1.38E-02 4.0 1.30E-02 1.57E-02 0.7 1.54E-02
Pancreas 1.40E-02 0.7 1.55E-02 1.37E-02 0.7 1.43E-02
Red marrow 9.71E-03 2.0 9.41E-03 1.04E-02 0.4 1.03E-02
Osteogenic cells 1.39E-02 3.6 1.26E-02 1.57E-02 0.8 1.53E-02
Skin 7.22E-03 3.7 6.73E-03 8.17E-03 0.7 8.00E-03
Spleen 1.52E-02 7.9 1.50E-02 1.15E-02 0.5 1.16E-02
Testes 1.58E-02 6.6 1.13E-01 1.25E-02 5.1 6.41E-02
Thymus 9.26E-03 3.5 8.39E-03 1.09E-02 0.8 1.01E-02
Thyroid 8.86E-03 4.1 7.62E-03 1.01E-02 0.9 9.63E-03
Urinary bladder wall 1.54E-01 0.3 1.54E-01 1.56E-01 0.0 1.56E-01
Uterus 1.90E-02 2.9 1.82E-02 2.09E-02 0.5 2.06E-02
Total body 1.19E-02 0.0 1.21E-02 1.18E-02 0.4 1.19E-02
Effective dose (mSv/MBq) 1.88E-02 2.7 2.72E-02 1.84E-02 1.9 2.19E-02
Human absorbed dose (mGy/MBq) and effective dose for ICRP 103 weighting factors (mSv/MBq) derived by animal tissue distribution (TD) and dynamic imaging
based on single sphere segmentation (both bladder fraction 0.5) for the standard 70-kg male phantom including no extrapolation (NE) estimation based on pure
animal data.
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sion of geometric transfer matrix [18], but it requires the
point spread function of the system and accurate anatom-
ical information (ideally from MRI). Another, simpler ap-
proach to overcome these limitations that could be useful
is a combined method where animals are sacrificed after
dynamic imaging, and the activity of the harvested organs
is quantified with a gamma well counter to cross-calibrate
organ activity measured with microPET. Kesner et al.
applied this approach to dosimetry in rats [15]. An investi-
gation of this approach in mice, where size dependent ef-
fects are more eminent than in rats, will be part of future
studies. Furthermore, movement artifacts arising due to
rapid respiration and heart motion could be avoided by
gated scanning [19]. However, it should be noted that
gating decreases signal to noise ratios and leads to longer
and fewer frames. An iodine-based contrast agent was
used to aid organ delineation in the microCT scans.Although of great use in organ delineation, this contrast
agent is most likely cleared via the same pathways as the
tracer and might thus have altered uptake in liver and
kidneys. The effect of IP contrast agent on residence times
in the TD method will be considered in future studies.
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derived by TD and dynamic single was r = 0.9666
(p < 0.0001) and r = 0.9603 (p < 0.0001) between TD and
dynamic whole. The largest absolute differences in
absorbed dose were found in brain, liver, and kidneys,
which were underestimated in dynamic imaging by 72%
(expressed as percentage of absorbed dose derived by
organ harvesting), 46% and 37%, respectively. Since the
brain data in dynamic imaging were derived from the
remainder, the large deviation in absorbed dose for brain
is a logical consequence of the methodology, as opposed
to liver and kidneys, which were clearly derived by both
methods. However, the effective dose deviated by only
approximately 2%.
In comparison to the effective dose for 18F-FDG using
the 70-kg adult male phantom, [18F]UCB-H remained
below the reported effective dose for FDG of 2.1E-02 to
2.9E-02 mSv/MBq [20] with values (based on ICRP 103)
of 1.88E-02 mSv/MBq (TD) and 1.84E-02 mSv/MBq
(dynamic single). Based on the old tissue weighting factors
from ICRP 60, the effective dose was 2.18E-02 mSv/MBq
(TD) and 2.15E-02 mSv/MBq (dynamic single). These
values are also well below the limits given by the ICRP
[21]. When assuming a smaller bladder fraction of 0.3,
the effective dose based on TD is decreased to an aver-
age of 1.66E-02 mSv/MBq (dynamic single 1.63E-02
mSv/MBq, both ICRP 103) for the standard 70-kg male.
Assuming a shorter voiding interval (pre-scan hydration
of the subject) of 2 h, the effective dose further
decreases to 1.65E-02 mSv/MBq (TD and ICRP 103;
1.61E-02 mSv/MBq for dynamic single) for a bladder
fraction of 0.5 and 1.53E-02 mSv/MBq (TD and ICRP
103; 1.49E-02 mSv/MBq for dynamic single) for a
bladder fraction of 0.3.
The dose limits described by the US Food and Drug
Administration (expressed in equivalent dose, equal to
absorbed dose in this case, radiation weighting factor equal
to 1) state that 30 mSv per scan should not be exceeded, or
an annual dose of 50 mSv for whole body, blood forming
organs, lens of the eye and gonads. The limits for all other
organs are 50 mSv (single scan) and 150 mSv (annual) [22].
Therefore, for research in the USA, the maximum single
injected dose of [18F]UCB-H allowed (assuming a bladder
fraction of 0.5 and ICRP 103 factors) is 325 MBq, while the
maximum annual dose is 974 MBq, with the urinary
bladder being the critical organ for both (values derived
from TD; dynamic imaging yields very similar values of 321
and 962 MBq). When decreasing the bladder fraction to
0.3, the critical organ remains the urinary bladder, but the
single and annual doses increase to 517 MBq for single
injection and 1,551 MBq for annual injection (508 MBq/
1,523 MBq dynamic imaging). European regulations
propose that the effective dose should not exceed 10 mSv
per scan [21]. Based on this more stringent criterion, themaximum injectable dose per scan derived by organ
harvesting would be 532 MBq per subject (543 MBq
dynamic single). If the bladder fraction is only 0.3, the
maximum injectable dose is 601 MBq (614 MBq dynamic
single). However, the presently derived injection limits
represent a worst case scenario due to assumptions made,
such as physical decay only after the last measured time
point or the relatively high fraction of injected activity
cleared via urinary pathways. First human clinical trials are
indispensable for confirming injection limits.
In displacement studies, subjects are injected at least
twice in a short time interval in order to detect the baseline
state and the activation state, or displacement [23]. There-
fore, a limit of 300 MBq per scan will keep radiation
exposure below harmful limits with an annual limit of three
injections for practice in the USA. However, based on the
high amount of activity reaching the brain [2], the injection
of 200 MBq per scan ought to be sufficient to provide
diagnostically useful images with [18F]UCB-H.
Conclusions
In this study, it was shown that the novel SV2A radiotracer
[18F]UCB-H meets the standard regulations regarding
radiation dose for use in human clinical trials. A maximum
single injectable dose of approximately 325 MBq per scan
was estimated based on the classical organ harvesting
technique. Dynamic imaging results by microPET showed
significant deviations from organ harvesting results for
single-organ absorbed doses, indicating that accurate
quantification in such small volumes as mice organs is lim-
ited. However, the effective dose derived by microPET devi-
ated by only 2% from the classical organ harvesting result.
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